HIV Weekly - 29th May 2013

A round-up of the latest HIV news, for people living with HIV in the UK and beyond.

The HIV epidemic in London

New figures provide further evidence of the beneficial effects of antiretroviral treatment and the excellent prognosis of many people living with HIV.

A total of 31,000 people were receiving HIV care in London in 2011. But there were only 159 new AIDS diagnoses and 169 HIV-related deaths.

Late diagnosis of HIV continues to be a major problem, and doubtless contributed to the above morbidity and mortality figures.

UK HIV treatment guidelines recommend that most people living with HIV should start HIV treatment when their CD4 cell count is around 350.

However, 44% of people newly diagnosed with HIV in 2011 had a CD4 cell count below this figure, and a quarter had a CD4 cell count below 200, showing they were at high risk of developing serious HIV-related disease.

Approximately a fifth of HIV infections in the UK capital are thought to be undiagnosed, meaning that a significant number of people are not accessing the care they need to stay well. This also undermines the beneficial effects of HIV treatment as a method of preventing HIV transmission. Other research shows that up to 50% of all new HIV transmissions may originate in people who are unaware that they have HIV.

Gay men and African people remain the groups most affected by HIV in London. But the report also highlighted increased numbers of new heterosexual diagnoses due to transmission in the UK.

Falling HIV mortality in China

Expanded access to antiretroviral treatment in China has been accompanied by big falls in HIV-related mortality.

Free HIV treatment started to be rolled out across China in 2009. Researchers looked at the impact of expanded access to treatment on mortality figures until 2009.

They found that mortality rates fell substantially. The research also showed the importance of starting treatment before HIV has done extensive damage to the immune system.

However, comparison with matched HIV-negative individuals in the general population showed that even with treatment, mortality rates were still higher in people with HIV.

But the researchers believe that improvements in HIV treatment and care will further reduce the mortality risk for people living with HIV in China.

Access to hepatitis C treatment in Europe

There are huge differences between European countries in the proportion of people with hepatitis C virus (HCV) who access treatment, new research shows.

Estimates were for 2010. This was the last year of dual therapy with pegylated interferon and ribavirin. In 2011, two new HCV protease inhibitors were approved and can improve treatment response rates.

France had the highest treatment rate. In 2010, approximately 7% of people with hepatitis C accessed treatment. However, only 0.8% of Italian patients received treatment in the same year.

Perhaps because of cost, hepatitis C treatment rates were low in Russia (0.3%), Poland (0.4%) and Romania (1%).

They were also low in a number of richer European countries, including Belgium, Finland and Ireland (each 1-1.5%).

The uptake of treatment was better in the UK (3.4%), Germany (4.3%) and Sweden (4.3%).

AZT and CD4 cell count

HIV treatment based on AZT is associated with lower CD4 cell gains than combinations based on other anti-HIV drugs, new research shows.

AZT (zidovudine, Retrovir) is now rarely used in routine long-term HIV therapy in the UK. However, it remains a mainstay of treatment in parts of Africa and other resource-poor settings. Viral load monitoring isn’t routinely available in many poorer countries. Decisions about changes in HIV treatment are therefore usually made on the basis of CD4 cell count and symptoms.

If AZT is associated with poorer CD4 cell gains, it could mean that some people are changing treatment unnecessarily.

Researchers looked at increases in CD4 cell count among 72,500 people starting HIV treatment in four African countries. Twenty-seven percent received therapy with AZT.

Five years after starting treatment, people taking AZT had smaller CD4 gains compared to people taking another drug.

This difference persisted when the researchers limited their analysis to the people who had an undetectable viral load.